116 related articles for article (PubMed ID: 26416061)
21. [Relationship between expression of p57(kip2), cyclin E protein, PCNA, and clinicopathological factors in human pancreatic cancer].
Yue H; Zhang N; Feng XL; Ma SR; Song FL; Yang M; Tang YH
Ai Zheng; 2003 Jul; 22(7):705-9. PubMed ID: 12866960
[TBL] [Abstract][Full Text] [Related]
22. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
23. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases.
Fukuse T; Hirata T; Naiki H; Hitomi S; Wada H
Cancer; 1999 Oct; 86(7):1174-81. PubMed ID: 10506701
[TBL] [Abstract][Full Text] [Related]
24. p53 expression in non small cell lung cancer: clinical and biological correlations.
Fontanini G; Bigini D; Vignati S; Macchiarini P; Pepe S; Angeletti CA; Pingitore R; Squartini F
Anticancer Res; 1993; 13(3):737-42. PubMed ID: 8100413
[TBL] [Abstract][Full Text] [Related]
25. Proliferating cell nuclear antigen promotes cell proliferation and tumorigenesis by up-regulating STAT3 in non-small cell lung cancer.
Wang L; Kong W; Liu B; Zhang X
Biomed Pharmacother; 2018 Aug; 104():595-602. PubMed ID: 29803172
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer.
Yuan A; Yang PC; Yu CJ; Chen WJ; Lin FY; Kuo SH; Luh KT
Am J Respir Crit Care Med; 2000 Nov; 162(5):1957-63. PubMed ID: 11069840
[TBL] [Abstract][Full Text] [Related]
27. The expression of proliferating cell nuclear antigen (PCNA) and p 53 protein correlate with prognosis of patients with oral squamous cell carcinoma.
Kurokawa H; Yamashita Y; Takeda S; Miura K; Murata T; Kajiyama M
Fukuoka Igaku Zasshi; 1999 Jan; 90(1):6-13. PubMed ID: 10087668
[TBL] [Abstract][Full Text] [Related]
28. Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data.
Fontanini G; Pingitore R; Bigini D; Vignati S; Pepe S; Ruggiero A; Macchiarini P
Am J Pathol; 1992 Dec; 141(6):1285-90. PubMed ID: 1361306
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer.
Ye X; Ling B; Xu H; Li G; Zhao X; Xu J; Liu J; Liu L
Medicine (Baltimore); 2020 Apr; 99(16):e19755. PubMed ID: 32311975
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.
Wang Y; Dong QZ; Fu L; Stoecker M; Wang E; Wang EH
Mol Carcinog; 2013 Nov; 52(11):890-9. PubMed ID: 22753141
[TBL] [Abstract][Full Text] [Related]
31. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
32. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Zhang Z; Ma J; Li N; Sun N; Wang C
Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
[TBL] [Abstract][Full Text] [Related]
33. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
34. The role of LGR5 and ALDH1A1 in non-small cell lung cancer: Cancer progression and prognosis.
Gao F; Zhou B; Xu JC; Gao X; Li SX; Zhu GC; Zhang XG; Yang C
Biochem Biophys Res Commun; 2015 Jun; 462(2):91-8. PubMed ID: 25881507
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
36. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
37. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
Li L; Mei TH; Zhou XD; Zhang XG
Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.
Xu YH; Lu S
Eur J Surg Oncol; 2014 Mar; 40(3):311-7. PubMed ID: 24332948
[TBL] [Abstract][Full Text] [Related]
39. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer.
Lin Q; Chen T; Lin Q; Lin G; Lin J; Chen G; Guo L
J Surg Oncol; 2013 Jun; 107(7):767-71. PubMed ID: 23609137
[TBL] [Abstract][Full Text] [Related]
40. [PCNA (proliferating cell nuclear antigen) expression in adenocarcinomas < 2 cm of the peripheral lung].
Koshikawa T; Nakamura S; Kitoh K; Hayashi K; Suyama M; Kunishima K
Rinsho Byori; 1993 Jun; Suppl 94():113-24. PubMed ID: 8103122
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
